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12‑O‑Tetradecanoylphorbol‑13‑acetate​(TPA)​is​the​most​widely​used​diacylglycerol​(DAG)​mimetic​
agent​and​inducer​of​protein​kinase​C​(PKC)‑mediated​cellular​response​in​biomedical​studies.​TPA​has​
been​proposed​as​a​pluripotent​cell​differentiation​factor,​but​results​obtained​have​been​inconsistent.​
In​the​present​study​we​show​that​TPA​can​be​applied​as​a​cardiomyogenesis‑promoting​factor​for​
the​differentiation​of​mouse​embryonic​stem​(mES)​cells​in​vitro.​The​mechanism​of​TPA​action​is​
mediated​by​the​induction​of​extracellular​signal‑regulated​kinase​(ERK)​activity​and​the​subsequent​
phosphorylation​of​GATA4​transcription​factor.​Interestingly,​general​mitogens​(FGF,​EGF,​VEGF​and​
serum)​or​canonical​WNT​signalling​did​not​mimic​the​effect​of​TPA.​Moreover,​on​the​basis​of​our​
results,​we​postulate​that​a​TPA‑sensitive​population​of​cardiac​progenitor​cells​exists​at​a​certain​time​
point​(after​days​6–8​of​the​differentiation​protocol)​and​that​the​proposed​treatment​can​be​used​to​
increase​the​multiplication​of​ES​cell‑derived​cardiomyocytes.
Pluripotent stem (PS) cells represent a promising source of cardiomyocytes for cell-based therapies and a model 
for cardiac  disease1. The cardiomyogenic differentiation of PS cells is an intensively investigated and already 
relatively well-described process. There are a number of efficient protocols for cardiomyocyte generation from 
PS cells, mainly based on in vivo and in vitro heart development studies. The most efficient protocols employ 
various growth factors (GFs), such as WNT, BMP, and FGF, to reinforce mesoderm and/or cardiac mesoderm 
differentiation during the initial steps. In the following phase, cardiac specification and maturation are driven by 
Dickkopf and Noggin—antagonists of the WNT and BMP pathways, respectively. Also, various well-characterised 
small-molecule compounds can be employed to imitate cellular responses to naturally occurring protein ligands 
involved in the aforementioned signalling  pathways2–4. 12-O-Tetradecanoylphorbol-13-acetate (TPA) is a very 
potent small-molecule compound. It is standardly used in biomedical research as an activator of the protein 
kinase C (PKC) family, a broad group of serine/threonine  kinases5,6. PKC signalling mediates a number of cel-
lular processes, including the regulation of cell proliferation, differentiation, and migration, etc.7–9. Members 
of the PKC family are divided into three subfamilies on the basis of their mechanisms of activation. Classical 
PKCs require diacylglycerol (DAG),  Ca2+ and acidic membrane phospholipids. Novel PKCs rely on DAG and 
acidic phospholipids. Atypical PKCs are reliant upon acidic phospholipids only. TPA mimics the action of DAG; 
therefore, it is involved in the activation of classical and novel  PKCs10. TPA also triggers certain MAP kinase 
pathways and their downstream signalling  events11.
In this study, we analysed the effect of TPA on cardiomyocyte formation in mouse embryonic stem (ES) 
cells. It was demonstrated that particular PKCs are associated with the regulation of  cardiomyogenesis12. A 
study by Sachinidis et al. showed the inhibition of cardiomyocyte development after the TPA treatment of 
mES  cells13. On the other hand, Feng et al. indicated that TPA induces the formation of endodermal lineage 
in human ES cells through  PKC14, which can promote cardiac  formation15. We showed that TPA treatment 
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stimulates cardiomyogenesis in differentiating mES cells. This treatment increased the number of cardiomyocytes 
by approximately 5 times compared to the standard protocol of differentiation, which is based on spontaneous 
cardiomyogenesis induced by the formation of embryonic bodies. Surprisingly, the observed effect was lim-
ited to the specific time window at around Day 6 of differentiation. Thus, we suggest that stimulation by TPA 
targets the population of cardio-mesodermal progenitors. However, the accumulation of cellular response to 
prolonged treatment was not present. Various hypotheses about TPA’s mode of action were evaluated, includ-
ing ERK and canonical WNT signalling cascades. In conclusion, our results show that the activation of PKC by 
TPA and subsequent stimulation of ERK at the specific time point increases the formation of cardiomyocytes 
in differentiating ES cells.
Materials​and​methods
Cell​culture​and​cardiomyocyte​differentiation.​ The undifferentiated mouse ES D3 line and R1 cell 
line and its subclones HG8, NK4 and TfR1 were adapted to feeder-free culture and routinely cultivated, as 
described  previously16,17. R1_MHC-neor/pGK-hygro ES cells (HG8 cell line), carrying the Myh6 promoter regu-
lating the expression of neomycin phosphotransferase, were prepared by the transfection of R1 cells by MHC-
neor/pGK-hygro plasmid (kindly provided by Dr. Loren J. Field, Krannert Institute of Cardiology, Indianapolis, 
US). R1_NKX2.5-GFP ES cells (clone NK4) carrying the Nkx2.5 promoter-GFP reporter were prepared by the 
transfection of R1 cells with NKX2-5-Emerald GFP BAC  reporter18. TfR1 ES cells were prepared by the transfec-
tion of R1 cells with Super8X TOPflash  construct19. Cells were cultivated in DMEM media supplemented with 
15% FBS, 100  IU/ml penicillin, 0.1  mg/ml streptomycin, and 1 × non-essential amino acid (all from Gibco-
Invitrogen) and 0.05 mM β-mercaptoethanol (Sigma), supplemented with 1,000 U/ml of leukemia inhibitory 
factor (LIF, Chemicon), here referred to as complete ES medium. Cardiomyogenic differentiation was induced 
by the seeding of ES cells to form embryoid bodies (EBs). EB formation was induced by ES cell cultivation 
(2 × 105 cells per ml) on bacteriological dishes coated with 1% agar in complete ES medium without LIF or by the 
hanging drop method (each EB was generated from 400 cells). In the next step, 5-day-old EBs were transferred 
onto adherent tissue culture dishes and cultivated in DMEM-F12 (1:1) supplemented with insulin, transfer-
rin, selenium (ITS, Gibco-Invitrogene), and antibiotics (as above), i.e. the serum-free medium. The cell culture 
medium was replaced every 2 days. Selected intracellular signalling pathways were inhibited by the following 
drugs: CHIR99021 (inhibitor of GSK3 kinase), Go6976 (PKC inhibitor), Go6983 (PKC inhibitor), Chelerythrine 
chloride (PKC inhibitor), UO126 (inhibitor of MEK/ERK), and PD184352 (an inhibitor of MEK/ERK) (all from 
Sigma-Aldrich). In addition, recombinant WNT3A (R&D Systems) or WNT3A-conditioned medium were used 
for canonical Wnt pathway  activation20 and FGF, EGF and VEGF (all Peprotech) for MEK/ERK pathway activa-
tion. TPA (P1585, Sigma-Aldrich) was used for PKC activation.
Counting​of​cardiomyocytes.​ In each experiment the same initial number of ES cells were used, and each 
sample was derived from the same number of EBs. The relative number of cardiomyocytes in differentiating ES 
cell cultures was determined using the HG8 cell line as described  before16. Briefly, cells were differentiated as 
mentioned above and on Day 14 and/or 20, MYH6-positive cardiomyocytes were selected by G418 antibiotic 
for six days. Estimation of the relative number of viable cells after antibiotic selection was performed by ATP 
quantification in whole cell lysates.
The direct counting of cardiomyocytes in differentiating ES cell cultures was performed using R1 cells as 
described  before16. Briefly, EBs were seeded individually onto 24-well plates. On day 20, EBs were washed with 
phosphate buffered saline (PBS), incubated in a 0.3% solution of Collagenase II (Gibco) in DMEM media without 
serum for 20 min, and then incubated in trypsin (0.25% in PBS-EDTA, Gibco) for 5 min. Enzymes were inacti-
vated by washing the cells with ES medium. Cells derived from each EB were seeded individually onto gelatinised 
cell culture wells. The next day, cells were washed with PBS, fixed with 4% formaldehyde, permeabilised by a 
0.1% Triton X-100 solution in PBS, and blocked in 1% bovine serum albumin in PBS. Then, cells were incubated 
overnight at 4 °C with anti-cardiomyocyte heavy myosine antibody (anti-MHC, clone MF20, kindly provided by 
Dr. Donald Fischman, Developmental Studies Hybridoma Bank, Iowa City, IA, USA). The following day, cells 
were incubated with anti-mouse IgG conjugate Alexa488 (Invitrogen) for 1 h at RT. Nuclei were counterstained 
with DAPI (1 mg/l). Subsequently the number of cardiomyocytes per single EB was calculated manually using 
an Olympus IX-51 inverted fluorescence microscope (Olympus). Representative images were acquired using an 
Olympus IX-51 inverted fluorescence microscope (Olympus).
The percentage of cardiomyocytes in differentiating R1 and D3 ES cell cultures was determined by flow 
cytometry. Briefly, 20-day-old EBs were dissociated, as mentioned above. Cells were fixed with 4% formaldehyde 
(20 min/4 °C), permeabilised by a 0.1% Triton X-100 solution in PBS (10 min/RT), and blocked in 1% BSA in 
PBS (30 min/RT). Then, cells were stained with anti-MHC antibody (1 h/RT), followed by staining with anti-
mouse IgG conjugate Alexa488 (1 h/RT). Simultaneously, negative controls—non-stained cells and cells stained 
only by secondary antibody—were prepared. Data were acquired with BD FACSVerse (BD Biosciences). Results 
were analyzed using NovoCyte software (ACEA Biosciences).
Analysis​of​gene​expression​by​qRT‑PCR.​ Total RNA was extracted by RNeasy Mini Kit (Qiagen). 
Complementary DNA was synthesised using RevertAid Reverse Transcriptase reverse transcriptase kit (Thermo 
Fisher Scientific) following the manufacturer’s instructions. qRT-PCR was performed in a Roche Light-cycler 
using the following program: 95 °C for 10 min followed by 45 cycles of 95 °C for 10 s, 60 °C for 30 s, and 72 °C 
for 1 s, with data acquisition. Results are expressed as the fold difference between the target gene and the ref-
erence gene, determined by the relative quantification 2−ΔCq method. The levels of cardiac transcripts were 
determined using a LightCycler Probes Master with UniversalProbe library probes (all from Roche, Germany) 
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according to the manufacturer’s instructions. Ribosomal protein L13A (Rpl13a) and Hprt were used as reference 
genes; primer sequences and probes are listed in Table 1.
Western‑blot​analysis.​ Cells were directly lysed in 100 mM Tris/HCl (pH 6.8), 20% glycerol, 1% SDS, 
0.01% bromophenol blue, and 1% 2-mercaptoethanol. Western blotting was performed according to the manu-
facturer’s instructions with minor modifications [SDS-PAGE run on 110 V, transfer onto PVDF membrane for 
1 h on 100 V (BIO-RAD)]. Membranes were blocked in 5% non-fat dry milk solution in TBS-T for 30 min 
and subsequently incubated overnight at 4  °C with the following primary antibodies: p-ERK1/2 (CS-4370S, 
Cell Signaling)21, ERK1/2 (CS-4695S, Cell Signaling)21, EGR1 (CS-4154, Cell Signaling)21, p-GATA4 (ab5245, 
Abcam)22, GATA4 (SC-25310, Santa Cruz Biotechnology)23, p-PKC (CS-9371, Cell Signaling)24, GFP ([3H9], 
Chromotek)25, β-Actin (CS-4970, Cell Signaling)26 and anti-cardiomyocyte myosine heavy chain antibody (anti-
MHC, clone MF20)27. Next, membranes were washed in TBS-T and incubated with HRP-conjugated second-
ary antibodies (Sigma-Aldrich). Immunoreactive bands were detected using ECL detection reagent kit (Merck-
Millipore) and the FusionSL chemiluminescence documentation system (Vilber-Lourmat). Western blot signals 
shown in the manuscript are present along with unprocessed and uncropped western blot images with molecular 
mass markers in the Supplementary Figures 13, 15, 17, 18, and 19. Western blot signals were obtained from 
membranes cut accordingly to the detected protein’s molecular size and incubated with primary and secondary 
antibodies alone to ascertain specific detection. This technique allows probing for various proteins using one 
membrane, but precludes the presence of full membranes. Therefore, the validation of signal specificity was 
performed using solvent- and TPA-treated samples (Supplementary Fig. 14, 16) and presented as full-size mem-
branes. Red boxes in the Supplementary Figures 14 and 16 indicate the cropping strategy used in the manuscript. 
Results were quantified (Supplementary Fig. 9) by the densitometric analysis of Western blot bands using the Fiji 
distribution of ImageJ.
TOPflash​luciferase​reporter​assay.​ Tfr1 cells, the R1 subclone carrying the TOPflash luciferase reporter 
plasmid, were cultured and differentiated in the same manner as the maternal R1 ES cell line. For cell stimula-
tion, recombinant WNT3A (R&D Systems), WNT3A conditioned media or control conditioned  media20, TPA, 
and CHIR99021 (Sigma-Aldrich) were added 12 h before harvesting. Luciferase assay kit (Promega, USA) was 
used according to the manufacturer’s instructions for the evaluation of luciferase activity. Relative luciferase 
units were measured on a Chameleon V luminometer (Hidex, Finland) and normalized to the cell mass.
Measurement​of​reactive​oxygen​species​induced​by​TPA.​ Human HL-60 cells were grown in RPMI 
1640 (LM-R1640, Biosera) supplemented with 10% FBS and 100 IU/ml penicillin, and 0.1 mg/ml streptomycin 
at 37 °C in a 5%  CO2 atmosphere. To differentiate HL60 cells into neutrophil-like cells, 1.3% DMSO was added 
to the medium for 5–7 days, as previously  described28,29. The measurement of ROS was performed as reported 
 before29,30. Briefly, cells were washed twice with serum-free and phenol-free medium. The reaction mixture con-
sisted of 2.5 × 105 cells, PKC/ERK inhibitor, 2 mM luminol (Sigma-Aldrich), and TPA. A total reaction volume of 
120 µL was adjusted with serum-free, phenol-free medium. Assays were run in duplicates. Chemiluminescence 
(CL) emission, expressed as relative light units, was recorded continuously for 90 min at RT on a Chameleon V 
luminometer (Hidex, Finland). The results of the CL reaction are presented as total ROS production (manifested 
by luminescence measurements) in dependence on time.
Isolation​of​mouse​hearts.​ CD1 mice were maintained and bred under standard conditions and were 
used in accordance with the European Community Guidelines of accepted principles for the use of experimental 
animals. Mouse hearts were isolated according to an experimental protocol that was approved by the National 
and Institutional Ethics Committee (protocol MSMT-18110/2017-5). Embryonic hearts were collected from 
E8, E12, E13, E18 embryos isolated from sacrificed pregnant mice. Neonatal hearts were excised from newborn 
mice, whereas adult hearts were derived from male 2–4-months-old mice. Isolated hearts were kept on ice in 
Table 1.  Probes and sequences of primers used in quantitative RT-PCR.
Gene of interest Forward primer 5′ → 3′ Reverse primer 5′ → 3′ UPL probe no
Hprt tcctcctcagaccgctttt cctggttcatcatcgctaatc #95
Rpl13a ccctccaccctatgacaaga gccccaggtaagcaaactt #108
Nkx2.5 gacgtagcctggtgtctcg gtgtggaatccgtcgaaagt #53
Myh6 cgcatcaaggagctcacc cctgcagccgcattaagt #6
Myh7 cgcatcaaggagctcacc ctgcagccgcagtaggtt #6
Myl2 gtttgagcagacccagatcc ttgtcgatgaagccgtctct #93
Myl7 cccatcaacttcaccgtctt aacatgcggaaggcactc #7
Mef2c accccaatcttctgccact gatctccgcccatcagac #6
Gata4 ggaagacaccccaatctcg catggccccacaattgac #13
T actggtctagcctcggagtg ttgctcacagaccagagactg #27
Mesp1 acccatcgttcctgtacgc gcatgtcgctgctgaagag #89
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cold PBS during subsequent manipulations. Whole hearts and separated atria and ventricles were immediately 
frozen. Subsequently, tissue was dissociated in lysis buffer (Qiagen) by tissue grinding pestle (Serva) and samples 
were processed as described in paragraph 2.3. Each sample of embryonic heart was formed from a pool of 4 
hearts; samples of neonatal and adult hearts and their parts were formed from single hearts.
Statistical​analysis.​ Data are expressed as the mean ± SEM. Statistical analysis was assessed by one-way 
analysis of variance ANOVA, and Bonferroni’s Multiple Comparison post-test or t-test values of P < 0.05 were 
considered statistically significant.
Results
TPA​increases​cardiomyocyte​formation​in​mES​cells.​ Differentiating mES cells were treated with 
1 µM TPA at various time intervals (1 µM TPA had the most evident effect in the preliminary tested concentra-
tion range of 0.01–2 µM; Supplementary Fig. 1 demonstrates the effect of 0.1 and 1 µM TPA). The number of 
cardiomyocytes was evaluated on Days 20 and 26 (Fig. 1). First, cells were exposed to TPA continuously from 
Day 0 to Day 14 and from Day 6 to Day 14. As a result, we obtained an approximately 3-times-higher yield of 
cardiomyocytes on Days 20 and 26 of differentiation for the treatment interval from Day 6 to Day 14 (Fig. 2A,C). 
Then, we examined whether the same effect could be achieved for other time periods (Day 0–Day 2, Day 6–Day 
8, and Day 10–Day 12). Interestingly, the most pronounced result was obtained when the cells were exposed to 
TPA between Days 6 and 8 of differentiation (Fig. 2B,D). To further characterize the number of developing car-
diomyocytes, flow cytometric analysis of myosine heavy chain (MHC)-positive cells was employed. Only single 
cell populations without debris were taken into analysis and appropriate negative controls were used to adjust 
the gating (Supplementary Fig. 2A–A’’; 3A–A’’). We observed that upon TPA treatment from Day 6 to Day 8 the 
number of MHC-positive cells increased approximately two times, whereas TPA exposition from Day 10 to Day 
12 had no effect (Fig. 3A,B and Supplementary Fig. 3B,C). Because flow cytometry analysis gives information 
only about the relative number of cardiomyocytes, we also directly calculated the number of formed cardio-
myocytes per single EB. In accordance with previous data, the treatment interval from Day 6 to Day 8 had the 
most prominent effect on cardiomyogenesis (Fig. 3C,D). To avoid potential false-positive results caused by the 
presence of DMSO, a solvent of TPA, an additional control was added to our experimental scheme. DMSO was 
found to have no effect on cardiomyogenesis.
TPA​stimulates​cardiac​mesoderm​and​promotes​cardiomyogenesis.​ For further evaluation of 
the TPA-mediated effect on cardiomyogenesis, the expressions of cardiomyocyte-specific genes (Nkx2.5, Myh6, 
Myh7, Myl2, Myl7) were determined on Day 20 of differentiation by qRT-PCR. Cells treated with TPA (time 
Figure 1.  Experimental setup employed for comparison of the cardiomyogenic differentiation of ES cells 
exposed to different TPA treatment. Cells were treated with 1 µM of TPA on Days 0–2 (d 0–2), Days 0–14 (d 
0–14), Days 6–8 (d 6–8), Days 6–14 (d 6–14), and Days 10–12 (d 10–12) of differentiation. The number of 
cardiomyocytes was calculated on Days 20 and 26. Additionally, cardiomyocyte markers were analysed between 
Day 7 and Day 20 by qRT-PCR and Western blot method.
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window 6–8D) exhibited higher expressions of the aforementioned transcripts compared to controls (Fig. 4A–E 
and Supplementary Fig. 4A–E).
We also calculated the levels of Myl2 (ventricular cardiomyocyte isoform) and Myl7 (atrial cardiomyocyte 
isoform) gene transcripts, which are frequently used for description of the ventricular vs. atrial specification of 
ESC derived cardiomyocytes (Supplementary Fig. 5C,D)31,32. Their expression was normalised to the expression 
of transcription factor Nkx2.5 in order to elucidate the phenotype of cardiomyocytes. In contrast to myosin gene 
expression, the Nkx2.5 transcript level is relatively stable in cardiac precursor cells and cardiomyocytes. Moreover, 
it is independent of their phenotype and maturation (Supplementary Fig. 5)33,34. Thus, Nkx2.5 transcript can be 
used as a reference gene for cardiomyocytes within mixed cell populations such as differentiating ES cells. The 
expression of Myls was the same for all analysed groups (Fig. 4F,G and Supplementary Fig. 4F,G). Therefore, we 
can infer that TPA does not induce a change of cell phenotype.
Next, we analysed the expressions of cardiac mesoderm markers Mef2c (myocyte enhancer factor)35 and 
Gata436, and genes characteristic of cardiomyocytes, namely Nkx2.5 and Myh6, at different time points after 
TPA treatment. TPA did not affect Mef2c or Gata4 expression (Fig. 5A,B). However, levels of Nkx2.5 and Myh6 
transcripts were significantly increased—Nkx2.5 on Day 10 only, while Myh6 was increased on Days 10, 12, 14 
of differentiation (Fig. 5C,D). The expression of Myh6 transcript normalised to Nkx2.5 transcript was the same 
at all determined time points (Fig. 5E). This suggests that cardiomyocytes underwent multiplication rather than 
maturation.
Figure 2.  The effect of TPA treatment on the number of derived cardiomyocytes—indirect quantification. The 
number of cardiomyocytes was determined in HG8 cells treated with 0.1% DMSO and 1 µM TPA in different 
time windows (see Fig. 1). The selection of cardiomyocytes began on Day 14 and measurements were performed 
on Day 20 of differentiation (A, B). Selection of cardiomyocytes began on Day 20 and measurements were 
performed on Day 26 of differentiation (C, D). Data are presented as mean ± SEM, n ≥ 4. Statistical significance 
was determined by ANOVA with post hoc Bonferroni’s Multiple Comparison test; *P < 0.05; **P < 0.01; 
***P < 0.001.
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Figure 3.  The effect of TPA treatment on the number of derived cardiomyocytes—direct quantification. R1 cells 
were treated with 1 µM of TPA on Days 6–8 (d 6–8) Days 10–12 (d 10–12) of differentiation. Flow cytometric 
quantification of myosine heavy chains (MHCs) was performed on Day 20. Percentage of MHCs positive cells 
(A). Representative plots; gate R3 shows the percentage of MHC-positive cells (see Supplementary Fig. 2 for cell 
gating strategy) (B). Direct counting of MHC-positive cells by immunofluorescence staining. The number of 
MHC-positive cells per one embryoid body was calculated (C). Representative photos of cardiomyocytes (D). 
Red signal (MHCs), blue signal (DAPI, nuclear stain). Scale bar, 50 µm. Data are presented as mean ± SEM, 
n ≥ 3. Statistical significance was determined by ANOVA with post hoc Bonferroni’s Multiple Comparison test; * 
P < 0.05; **P < 0.01; ***P < 0.001.
7Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:15922  | https://doi.org/10.1038/s41598-020-73074-4
www.nature.com/scientificreports/
To verify the effect of TPA treatment also on the levels of cardiomyocyte-specific proteins, we performed 
Western blot analysis. Myosine heavy chains (MHCs) and NKX2.5 signals (determined as the level of GFP, the 
expression of which is driven by Nkx2.5 promotor) increased proportionally upon TPA treatment (Fig. 5F,H,I). 
The level of MHCs was significantly augmented from Day 10 of differentiation, whereas NKX2.5 protein expres-
sion escalated on Day 14, which indicates that TPA promotes cardiomyogenesis (Fig. 5H,I). To determine the 
maturation status of cardiomyocytes, we normalised MHCs to the level of NKX2.5 (Fig. 5G). The MHCs/NKX2.5 
ratio for TPA was significantly increased on Day 10 of differentiation, which could suggest the more progressed 
maturation status of cardiomyocytes. Interestingly, on Day 14, the ratio decreased significantly. Taken together, 
these data reveal that TPA induces the multiplication of cardiomyocyte progenitors, rather than their maturation. 
To support our hypothesis further, the employed cardiac differentiation protocol was characterized by means 
of gene expression analysis at different time points. The mesoderm marker T37,38 and the cardiac mesoderm 
marker Mesp138–40 became highly expressed from Day 3, peaking on Day 5 (Supplementary Fig. 6A,B). Later, 
the cardiomyocyte marker Nkx2.532,33 was upregulated from Day 5 and peaked on Day 15 (Supplementary 
Fig. 6C). Finally, cardiomyocyte myofilament gene Myh631,32 peaked on Day 15 of differentiation (Supplementary 
Fig. 6D). On the basis of these observations, we conclude that the population targeted by TPA corresponds to 
early cardio-mesoderm progenitors.
Role​of​the​ERK​pathway​in​cardiomyogenesis​through​TPA‑induced​PKC​signalling.​ To iden-
tify the mechanism of TPA action in cardiomyocyte multiplication, we employed various inhibitors targeting 
PKC- and ERK-related signalling. We combined TPA treatments with the aforementioned inhibitors to elucidate 
Figure 4.  The effect of TPA treatment on the expression of cardiomyocyte specific transcripts. Relative mRNA 
levels in R1 cells differentiated for 20 days and treated with 0.1% DMSO and 1 µM TPA between Day 6 and Day 
8 of differentiation, determined by qRT-PCR normalised to the mean expression of Hprt and Rpl13a genes (A–
E) or normalised to the Nkx2.5 gene (F, G). Data are presented as mean ± SEM, n ≥ 4. Statistical significance was 
determined by ANOVA with post hoc Bonferroni’s Multiple Comparison test; *P < 0.05; **P < 0.01; ***P < 0.001.
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Figure 5.  The TPA-mediated effect on the dynamics of the expression of cardiomyocyte specific transcripts 
at various time points. Relative mRNA levels of cardiac markers analysed at different time points of R1 cell 
differentiation determined by qRT-PCR, normalised to the mean expression of Hprt and Rpl13a genes (A–D) 
or normalised to Nkx2.5 gene expression (E). Western blot analysis of myosine heavy chains (MHCs) and 
NKX2.5 level (as level of GFP) at different time points of R1 cell (subclone NK4, see “Materials and methods”) 
differentiation (F). Ratio of MHC/NKX2.5 (G) and relative level of NKX2.5 (as level of GFP; H) and MHC (I) to 
β-Actin determined by densitometric analysis. Data are presented as mean ± SEM, n ≥ 4. Statistical significance was 
determined by ANOVA with post hoc Bonferroni’s Multiple Comparison test; *P < 0.05; **P < 0.01; ***P < 0.001.
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their effect on cardiomyocyte formation. As shown in Fig.  6A, Go6983—an inhibitor of PKC—significantly 
reduced the number of TPA-induced cardiomyocytes. In contrast, other inhibitors of PKC protein—namely, 
Go6976 and chelerythrine chloride—did not influence the quantity of cardiomyocytes (Supplementary Fig. 7A). 
At the same time, both used ERK signalling inhibitors (PD184352 and UO126) decreased cardiomyocyte yield 
(Fig. 6A). To ascertain that the decline in cardiomyocyte number was not mediated by the general anti-mito-
genic effect of PKC and ERK signalling inhibitors, we determined the total number of differentiated cells prior to 
cardiomyocyte selection under the tested conditions (on Day 14). Here, we did not detect any significant effect 
of TPA or inhibitors on the proliferation of these cells (Fig. 6B and Supplementary Fig. 7B). To confirm the role 
of TPA in PKC/ERK pathway activation in our model of cardiomyogenesis, we performed Western blot analysis 
of cells treated with TPA and inhibitors on Day 6 of differentiation. TPA induced the phosphorylation of PKC 
and ERK after 10 min, 30 min, and 1 h of exposure to TPA, thus showing their activation upon  treatment41,42. 
Moreover, 1 h of TPA treatment increased the level of EGR1, the expression of which is propagated by active 
ERK  signalling43 (Fig. 6C–E and Supplementary Fig. 7C,D; 8A–C; 9A–A’’, B–B’’, C–C’’).
Since TPA significantly activated PKC and ERK signalling, we investigated the effects of ERK activation and 
inhibition on the phosphorylation of GATA4. It is known that MAPKs cascades can modify the expression and 
activity of transcription factors by means of post-translational modifications such as  phosphorylation44. Our data 
demonstrate that TPA induced the phosphorylation of GATA4 in our model of cardiomyogenesis (Fig. 6C,D,E 
and Supplementary Fig. 7C,D; 8A–C; 9D–D’’). For further evaluation of the mechanism of TPA action, we 
inhibited the PKC pathway by various inhibitors. Go6983 blocked the TPA-dependent phosphorylation of PKC 
and ERK and reduced the level of EGR1, and, as a consequence, impeded GATA4 phosphorylation (Fig. 6C 
and Supplementary Fig. 8A; 9A–D). In contrast, other inhibitors of PKC–Go6976 and chelerythrine chloride 
(CHEL), did not cause this effect (Supplementary Fig. 7C,D). To study downstream events of PKC signaling, 
we applied specific ERK inhibitors. Treatments by both UO126 and PD184352 abolished the phosphorylation 
of GATA4 (Fig. 6D,E and Supplementary Fig. 8B,C; 9A’–D’, A’’–D’’). Interestingly, these inhibitors decreased the 
phosphorylation of PKC to some extent (Supplementary Fig. 9C’,C’’).
Taking these findings together with the results of cardiomyocyte counting (Fig. 6A and Supplementary 
Fig. 7A), we suggest that the positive effect of TPA on cardiomyocyte differentiation is mediated through the 
activation of the ERK signalling pathway by PKC. Moreover, our data suggest that TPA stimulates cardiac meso-
derm cells through the phosphorylation of GATA4 transcription factor.
Discussion
Our work shows that TPA is able to enhance the cardiomyogenesis of mouse ES cells. TPA induces the multi-
plication of cardiomyocyte progenitors through ERK signalling cascades and the subsequent phosphorylation 
of GATA4, which leads to an approximately 5-times-higher number of formed cardiomyocytes. Interestingly, 
this effect is specific to a relatively short time window of the differentiation process and is not strengthened by 
prolonged treatment.
TPA is known as a potent inducer of multiple signalling pathways in a PKC-dependent  manner45. TPA is 
frequently used in biomedical studies because of its ability to mimic diacylglycerol (DAG) and consequently 
activate classical and novel  PKCs10. PKCs are generally expressed in all tissues during embryonal  development46, 
but their isoforms differ in their tissue distributions and perform distinct biological  functions47. Interestingly, it 
was shown that, depending on the stimulation, individual PKCs can play antagonistic roles in the same  cells48. In 
addition, PKCs activated by TPA can also stimulate other signalling pathways—for instance MAPKs cascades, by 
the phosphorylation of downstream  components11. MAPKs are serine-threonine kinases involved in numerous 
processes, including those controlling cell proliferation and  differentiation49.
The role of PKCs and TPA in cardiomyogenesis in vitro is controversial and available data is contradictory. 
It was demonstrated that the downregulation of PKCβ, together with the upregulation of PKCε, are crucial for 
the formation of cardiomyocytes from ES  cells12,50,51. In contrast, Ventura et al. showed that PKCε and PKCβ 
levels increase during the process of cardiomyogenesis and that the inhibition of classical/novel PKCs impairs 
the formation of cardiac  cells52. However, Sachinidis et al. implied that the inhibition of PKC signalling improves 
cardiac formation, while TPA treatment decreases the yield of  cardiomyocytes13. Interestingly, TPA can rescue 
cardiomyogenesis altered by the disruption of FGF1/FGFR  signaling53. The reasons for such discrepancies are 
unclear. Possibly, they can be the result of the application of different cardiomyogenesis protocols, different tim-
ings of treatments, or the different complexities of the particular cardiomyogenesis evaluation methods employed.
The enhancement of cardiomyogenesis by TPA has not previously been recognized. We showed that TPA 
treatment and the activation of PKCs in a specific time window of differentiation strengthen cardiomygonesis.
Our results suggest that TPA-induced ERK1,2 activity and subsequent GATA4 phosphorylation is a key 
mechanism responsible for more pronounced cardiomyogenesis in mES cells. The extracellular signal-regulated 
kinases ERK1 and ERK2 are the best-characterised MAPKs, which also contribute to cardiac  development54. 
TPA induced both PKC and ERK phosphorylation and expression of the ERK target gene, Egr-143. Furthermore, 
inhibitors of ERK signalling diminished TPA-mediated activity, which confirms the important role of this path-
way in cardiac formation. In contrast, the effect of PKC inhibitors on TPA activation was not consistent. Only 
one inhibitor, Go6983, efficiently blocked TPA action. The observed discrepancies can be explained by inhibi-
tor specificity. Chelerythrine chloride was described as a potent PKC  inhibitor55. However, latest reports show 
that chelerythrine does not inhibit either basal or TPA-induced PKC  activity56. On the other hand, Go6976 was 
described as a strong inhibitor of PKCα and PKCβ isoforms, but not of novel PKC isozymes, which can also be 
activated by  TPA56. Nevertheless, we cannot state which isoform is responsible for the observed TPA effect on 
cardiomyogenesis. To address the question of inhibitor specificity towards PKCs, we performed additional tests 
based on the measurement of oxidative burst in neutrophil-like cells (Supplementary Fig. 10A,B). TPA activates 
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Figure 6.  The role of PKC and ERK signalling pathways in TPA-induced cardiomyogenesis. The number of cardiomyocytes was 
determined after the treatment of differentiated HG8 cells with the following inhibitors from Day 6 to Day 8: 1 µM Go6983, 1 µM 
PD184352, and 5 µM UO126 in combination with 1 µM TPA and 0.1% DMSO as solvent control. The selection of cardiomyocytes 
began on Day 14 and measurements were performed on Day 20 of differentiation (A). Fold of change in cell number for the 
non-selected population on Day 14 of differentiation after treatments corresponding to “A” (B). Western blot analysis of the 
phosphorylation status of PKC, ERK, and GATA4 and the level of EGR1 after the treatment of R1 cell-derived 6-day-old embryoid 
bodies with 0.1% DMSO or 1 µM TPA and the aforementioned inhibitors in the indicated time intervals (C–E). Data are presented as 
mean ± SEM, n ≥ 3. Statistical significance was determined by ANOVA with post hoc Bonferroni’s Multiple Comparison test; *P < 0.05; 
**P < 0.01; ***P < 0.001.
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PKC, which in turn promotes NADPH-dependent superoxide  production57. In our experimental model, Go6983 
inhibited the generation of reactive oxygen (ROS) species mediated by TPA, whereas Go6976 and ERK inhibi-
tors did not show any effect. Surprisingly, chelerythrine chloride worked similarly to Go6983. However, it was 
reported that the concentration of chelerythrine chloride which inhibits oxidative burst activated by TPA is 
not enough to inhibit the activity of  PKC58. Taken together, our results clearly indicate that TPA promotes the 
activation of the ERK pathway by PKC induction, followed by the phosphorylation of GATA4. Interestingly, 
TPA treatment promoted the phosphorylation of GATA4, but did not have any impact on the overall level of 
GATA4 expression. GATA4 phosphorylation increases its activity by means of an increase in DNA binding or 
by promoting interactions with co-activators, which leads to the promotion of the cardiac gene  program44,59.
The observed acceleration of cardiomyogenesis by TPA was limited to a relatively short time window (from 
Day 6 to Day 8). TPA treatment did not increase the level of Nkx2.5 transcripts immediately, so we suggest that 
TPA affects a subpopulation of NKX2.5-negative cardiomyogenic progenitors. We postulate that TPA affects 
Brachyury T- or Mesp1-positive cells. Brachyury T and Mesp1 are key genes regulating mesoderm and cardio-
myogenic mesoderm formation,  respectively60–62. In our experimental models, their expression peaked on day 5 
(Supplementary Fig. 6A,B), the time when TPA shows the most pronounced effect, which confirms our hypoth-
esis. Moreover, this effect seems to be specific to particular cells, because the overall mitogenic effect of TPA 
was not observed. Nevertheless, the identification of these cells will be the aim of further studies. Importantly, a 
recent study also showed that the activation of MAPK cascades was observed during a similar time window of 
cardiac differentiation (5–8 days)23.
To further characterise the TPA effect on ERK signalling, we tried to mimic its activity using growth factors. 
To this end, cells were treated with EGF, FGF2, VEGF, and serum. These factors are known to mediate mitogenic 
stimulation and activate ERK signalling in cells, which is also sensitive to PKC signalling  cascade45,63. Neverthe-
less, none of these inducers exhibited the effect delivered by TPA (Supplementary Fig. 11). However, these results 
can be affected by the insufficient stimulation of cells within compact EBs. It is known that in contrast to TPA, 
big hydrophilic proteins such as GF have limited ability to cross multi-layered  spheroids5,64,65.
Another pathway cross-reacting with TPA and PKCs is canonical WNT signalling. The formation of early 
cardiomyogenic mesoderm and its proliferation is regulated by the WNT/β-catenin  pathway66. The phosphoryla-
tion of LRP6, a key component of this pathway, is mediated by the activation of various MAPKs, which can be 
induced through TPA treatment. Phosphorylated LRP6 protein then significantly reinforces the WNT-mediated 
 signal67. We investigated whether TPA can strengthen WNT/β-catenin signalling and thus modify the dynamics 
of cardiomyogenesis. From Day 6 to Day 8, differentiating cells were treated with TPA, WNT3A, and the canoni-
cal WNT signalling mimetic CHIR99021, an inhibitor of GSK3 kinase. Similarly to previous results, TPA induced 
cardiomyocyte multiplication, whereas WNT3A and CHIR99021 had no effect (Supplementary Fig. 12). We did 
not observe any effect of TPA on canonical WNT signalling in our experiments, which shows that the observed 
cardiomyocyte multiplication was not WNT/β-catenin dependent.
In conclusion, we demonstrated that TPA can be used to reinforce cardiomyogenesis in mES cells. However, 
additional studies will be necessary to describe the mechanism of the TPA-induced multiplication of cardiac 
progenitors and to identify the target population of cardiomyocyte precursors.
Data​availability
The data that support the findings of this study are available from the corresponding author (Jiří Pacherník) 
upon reasonable request.
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